Infliximab Real World Studies: Switch Studies

Studies in Crohn’s Disease (CD) and Ulcerative Colitis (UC)46,47,53-55

Key Findings:

  • Demonstrated clinical efficacy46,47,53

- Across 13 real-world switch studies evaluating more than 800 IBD patients

  • Demonstrated biochemical improvements46,47,53-54

- In 5 real-word studies evaluating more than 400 IBD patients

   - C-reactive protein (CRP)46,47,53,54
   - Fecal calprotectin (FC)46-47 

  • A comparable tolerability profile to Remicade®†46,47,53,54

- Across 10 real-world studies evaluating more than 550 IBD patients

ECCO Position Statement on Biosimilars

ECCO Position Statement on Biosimilars – Danese S, et al. J Crohns Colitis 20175.

Click below to read more about Inflectra® evidence in IBD:

Induction and Maintenance

Paediatric Studies

Prescribing Information 

Inflectra® Summary of Product Characteristics   |   Legal Category: POM  Basic NHS Price: 1 vial £377.66

†Remicade® is a registered trademark of MSD.

IBD, Inflammatory bowel disease; ECCO, European Crohn's and Colitis Organisation.

 

 

PP-IFA-GBR-0308. December 2018